Vivid Dx raises $15M seed to speed up diagnosis of drug-resistant infections
What's the deal? Vivid Dx, an Oxford-based precision diagnostics company, has raised $15 million in seed financing to build a platform that identifies dangerous pathogens directly from blood. The round was co-led by Oxford Science EnterprisesDealroom has a profile for this one. Try Dealroom → and Cedars-Sinai Intellectual Property Co., with participation from Jameel Investment Management CompanyDealroom has a profile for this one. Try Dealroom → and other strategic investors.
What's the endgame? The company operates under the name Ramanomics and applies AI and advanced sample preparation to Raman spectroscopy, a technology that reads biochemical signatures from individual pathogen cells. Its platform aims to identify pathogens and support antimicrobial susceptibility testing directly from blood — cutting testing timelines from days to hours.
Why now? When a patient may have sepsis, every hour matters, yet hospitals often wait days to learn which pathogen is present and which antibiotics will work. During that window, clinicians rely on broad-spectrum antibiotics that may not defeat drug-resistant infections.
Researchers estimate antimicrobial resistance could contribute to 39 million deaths globally between 2025 and 2050. As hospitals face tighter antibiotic stewardship rules and pressure to protect last-line therapies, faster diagnostics are becoming essential.
The new boss: Vivid Dx also appointed scientist and diagnostics executive Keith O'Neill as chief executive officer to lead its clinical and commercial development. O'Neill previously worked at MIT on the Human Genome Project, built a point-of-care diagnostics program, and supported early-stage life sciences companies through Enterprise Ireland.
"For decades, clinicians treating serious infections have had to wait too long for the information needed to guide antibiotic treatment," O'Neill said. His focus, he added, will be advancing the technology "through clinical validation and toward a platform that clinicians can adopt routinely."
What could go wrong? Rapid diagnostics face a persistent challenge: answers must be fast but also accurate, broad enough to guide treatment, and practical for clinical workflows. The platform still needs to complete clinical validation before hospitals can adopt it.
The signal: At $15 million, the seed round sits in the top 2% of all UK health seed deals on record, based on 2,038 comparable rounds. That scale of early backing reflects mounting investor conviction that faster pathogen detection is central to confronting antimicrobial resistance.
Image credit: U.S. Department of Energy
